Chemically stable inhibitors of 14-3-3 protein–protein interactions derived from BV02 by Iralde-Lorente, Leire et al.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=ienz20
Journal of Enzyme Inhibition and Medicinal Chemistry
ISSN: 1475-6366 (Print) 1475-6374 (Online) Journal homepage: https://www.tandfonline.com/loi/ienz20
Chemically stable inhibitors of 14-3-3
protein–protein interactions derived from BV02
Leire Iralde-Lorente, Ylenia Cau, Letizia Clementi, Lorenzo Franci, Giusy
Tassone, Daniela Valensin, Mattia Mori, Adriano Angelucci, Mario Chiariello
& Maurizio Botta
To cite this article: Leire Iralde-Lorente, Ylenia Cau, Letizia Clementi, Lorenzo Franci, Giusy
Tassone, Daniela Valensin, Mattia Mori, Adriano Angelucci, Mario Chiariello & Maurizio
Botta (2019) Chemically stable inhibitors of 14-3-3 protein–protein interactions derived
from BV02, Journal of Enzyme Inhibition and Medicinal Chemistry, 34:1, 657-664, DOI:
10.1080/14756366.2019.1574779
To link to this article:  https://doi.org/10.1080/14756366.2019.1574779
© 2019 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
Published online: 07 Feb 2019.
Submit your article to this journal 
Article views: 345
View Crossmark data
RESEARCH PAPER
Chemically stable inhibitors of 14-3-3 protein–protein interactions derived
from BV02
Leire Iralde-Lorentea, Ylenia Caua, Letizia Clementib, Lorenzo Francic,d,e, Giusy Tassonea, Daniela Valensina,
Mattia Moria, Adriano Angeluccib , Mario Chiarielloc,e and Maurizio Bottaa,f,g
aDepartment of Biotechnology, Chemistry and Pharmacy, Universita degli Studi di Siena, Siena, Italy;bDepartment of Biotechnological and
Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy;cIstituto per lo Studio, la Prevenzione e la Rete Oncologica (ISPRO), Siena,
Italy;dDepartment of Medical Biotechnologies, PhD course GenOMeC, Universita degli Studi di Siena, Siena, Italy; eConsiglio Nazionale delle
Ricerche, Istituto di Fisiologia Clinica, Siena, Italy;fCenter for Biotechnology, College of Science and Technology, Sbarro Institute for Cancer
Research and Molecular Medicine, Temple University, Philadelphia, PA, USA;gLead Discovery Siena s.r.l., Siena, Italy
ABSTRACT
14-3-3 are regulatory proteins that through protein–protein interactions (PPI) with numerous binding part-
ners could be involved in several human diseases, including cancer, neurodegenerative disorders, and
pathogens infections. Following our research interest in the development of 14-3-3 PPI inhibitors, here we
exploited the privileged 4-aminoantipyrine scaffold in the design and synthesis of some derivatives
endowed with antiproliferative activity against K-562 cells, and capable of binding to recombinant 14-3-3r
as evidenced by NMR spectroscopy. The binding mode was further explored by molecular modelling,
while coupling confocal microscopy with intensitometric analysis showed that compound 1 was able to
promote the nuclear translocation of c-Abl at low micromolar concentrations. Overall, 1 is chemically sta-
ble compared to parent 14-3-3 PPI inhibitors, and thus emerged as a confirmed hit for further
development.
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Introduction
14-3-3 is a family of eukaryotic regulatory proteins that interact
with a multitude of different targets by means of protein–protein
interactions (PPI). To date, more than 500 partners of 14-3-3 have
been identified through biochemical and bioinformatics studies,
most of which are disease-relevant phosphorylated proteins shar-
ing the optimal binding sequence R(X)XpS/TXP1. In recent years,
14-3-3 proteins have emerged as profitable targets in the therapy
of several diseases including different types of cancer, neurodege-
nerative disorders, and pathogens infections1–4. In humans, seven
different isoforms have been characterised, which are commonly
named with Greek letters r, f, b, c, g, e, and s5,6. Although expres-
sion levels of specific 14-3-3 isoforms might vary in different tis-
sues, organs, or in particular disease conditions, these isoforms
share a significantly high degree of sequence and structural con-
servation7. Particularly, the binding site of phosphopeptides,
which is located within the so-called amphipathic groove and is
composed by a number of basic residues, is among the most con-
served portion of 14-3-3.
Our research group has long been involved in targeting 14-3-3
proteins as a strategy to treat chronic myeloid leukaemia
(CML)8–10. The first non-peptidic inhibitor of 14-3-3/c-Abl inter-
action (namely, BV02, Figure 1) has been discovered by virtual
screening of a commercial library of compounds. The molecule
was found to promote c-Abl translocation into the nucleus and to
provide antiproliferative effects also in CML cells expressing the
Imatinib-resistant T315I Bcr-Abl construct8. Since then, BV02 has
been used as tool compound in multiple biological studies aimed
at investigating the pharmacological inhibition of 14-3-3 PPI.
Notwithstanding, the molecule suffers from chemical instability in
aqueous buffer, which leads to the phthalimide derivative 9 by
means of a hydration/dehydration pathway (Figure 1)11. Thus, the
characterisation of the mechanism of action of BV02 has required
a combination of chemical, computational, and spectroscopic
studies, which have led to the identification of the phthalimide 9
as the bioactive form of BV02 in physiological conditions,
although the persistency of 9 was found to be strictly dependent
on the pH as well as the incubation time12.
To further shed light on the mechanism of 14-3-3 PPI inhibition
by the privileged 4-aminoantipyrine scaffold, and to identify novel
derivatives endowed with pharmacological properties comparable
to BV02/9 but endowed with a suitable chemical stability profile,
here we designed and synthesised three derivatives of the 14-3-3
PPI inhibitor 9. Interaction with 14-3-3r was monitored by NMR
spectroscopy and molecular modelling, while the mechanism of
action and anticancer potential were assayed in in vitro cancer
cell models.
Results and discussion
Chemistry
Compounds 1–3 were synthesised using the synthetic route out-
lined in Scheme 1. Starting from 4-aminoantipyrine and 1,2,4-
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benzenetricarboxylic anhydride, compound 9 was obtained in
quantitative yield after stirring at room temperature (r.t.) for 72 h.
Then, it was treated with AcOH and H2SO4 in the presence of tin
powder, which selectively reduces the carbonyl group of the
phthalimide moiety, to afford compound 1 in a high yield (79%).
To afford compound 2, acid chloride was prepared by reacting
compound 1 with oxalyl chloride and subsequently methylated by
the addition of MeOH into the reaction mixture. Synthesis of com-
pound 3 was completed after the reduction of the carboxylic
acid1 by borane dimethyl sulphide 1 M, leading to the primary
alcohol 3.
Compared to the parent 14-3-3 PPI inhibitor 9, chemical stabil-
ity at physiological conditions was remarkably improved by
removing one of the carbonyl groups from the phthalimide moi-
ety (compound 1), as observed by NMR spectroscopy (Figure 2).
Indeed, no variations in peaks chemical shift and multiplicity
within the aromatic region of the NMR spectrum of 1 in DMSO/
D2O 70:30 was observed, also after 24 h. According to the previous
analysis of the chemical stability of 912, this region was selected
as the most sensible to the hydration/dehydration pathway shown
in Figure 1. Besides NMR, chemical identity of compound 1 was
confirmed also by mass spectrometry after 24 h.
Antiproliferative activity of 1–3
Compounds 1–3 and the reference 14-3-3 PPI inhibitor 9 were
evaluated for their biological activity by in vitro model of human
erythroleukemia. Cancer cells K-562 were matched with increasing
concentration of the molecules, and incubated in standard culture
conditions for 72 h. Control K-562 cells were cultured with a per-
centage of DMSO vehicle (<0.1%) corresponding to that present
in the highest concentration of the compounds. At the end point,
cell number and viability were evaluated by automatic cell coun-
ter, and mean number of viable cells was expressed as percentage
with respect to control cells (Figure 3). Compounds 1 and 2
showed a significant reduction in viable cells with respect to the
control starting from the concentration of 1 mM. Notably, their
activity is highly comparable to that of the reference compound
9. The calculation of the concentration able to reduce by 50% the
number of viable cells with respect to control demonstrated that
evaluated compounds have IC50 ranging from 5.2 to 15.8 mM
(Figure 3). Compared to 1, 2, and 9, compound 3 affects the pro-
liferation of K-562 cells to a lesser extent. It is worth noting that
these data are in agreement with rough structure-activity relation-
ships (SAR) previously described for BV02 and compound 911,
showing that the carboxylic acid is a suitable functionality for the
pharmacophore to provide antiproliferative activity through inhib-
ition of 14-3-3 PPI, whereas the methyl ester is less effective.
Following this trend, the primary alcohol 3 showed indeed the
weakest antiproliferative activity.
Predicted binding mode of 1–3 to 14-3-3r
The possible binding mode of compounds 1–3 to the crystallo-
graphic structure of 14-3-3r was investigated by molecular dock-
ing simulations, which were carried out as described previously11.
Results clearly show that all compounds are able to fit the amphi-
pathic groove of 14-3-3, which is the well-known binding site of
14-3-3’s interaction partners. Moreover, the molecules interact
with the side chain of Arg56 and Arg129 that are relevant for the
binding of phosphorylated serine residues of 14-3-3 partners
(Figure 4). The key residue Lys49 is implicated in cation-p interac-
tions with the aromatic portion of the molecules. Additional
Figure 1. Chemical structure of the reference 14-3-3 PPI inhibitors 9 and BV02,
which are connected through a hydration/dehydration pathway.
Scheme 1. (i) DMAP, anhydrous DMF, r.t. for 72 h. (ii) Sn, HCl, AcOH, 80 C for 24 h. (iii) (COCl)2, DMF, THF for 1 h, then MeOH at 0 C. (iv) BH3Me2S at 0 C then
stirred at r.t. for 12 h.
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interactions are established with the side chain of Asn175 and
Lys122, while the hydrophobic portion of the 4-aminoantipyrine
occupies a non-polar part of the amphipathic groove in proximity
of Phe119, Ile168, Leu218, Ile219, and Leu222 (Figure 4).
It is worth mentioning that compounds 1–3 share a highly
consistent binding mode, which is also comparable to that already
described for the parent compound 9, with only a small difference
in the orientation of the N-methyl group of the pyrazolone ring.
This is indeed a consequence of the possibility to flip pyramidal N
atoms in GOLD docking program and does not affect significantly
the overall binding mode of 1–3.
Compounds 1 and 2 bind to recombinant 14-3-3r
The direct binding of 1 and 2 to recombinant 14-3-3r was prelim-
inarily assessed by screening techniques such as fluorescence
polarisation (FP) and surface plasmon resonance (SPR) (data not
shown). However, results were difficult to interpret, most likely
because of the relatively weak affinity of the molecules for 14-3-
3r. Thus, we decided to monitor the interaction between recom-
binant 14-3-3r and compounds 1 and 2 through 1H NMR spec-
troscopy by running transferred nuclear overhauser effect (Tr-NOE)
experiments. This approach is well established and relies on the
slow tumbling of the ligand when it is bound to specific protein
partners. In fact, ligand–protein interaction greatly enhances the
efficiency of the proton-proton NOE cross relaxation between pro-
tons of the ligand13.
Because of their size, 1 and 2 have negative NOE correlations
(positive NOEs enhancements) while 14-3-3-r has positive NOE
Figure 4. Predicted binding mode of compound 1 (A), 2 (B), and 3 (C) within
the amphipathic groove of 14-3-3r. The crystallographic structure of the protein
coded by PDB ID: 1YWT is shown as green cartoon; residues within 4 Å from the
ligands are shown as lines and are labeled. Ligand/protein polar contacts are
highlighted by black dashed lines. Ligands are shown as yellow sticks.
Figure 2. Aromatic region of 1H NMR spectra of molecule 1 in DMSO/D2O
(70:30) at r.t. recorded and different time points.
Figure 3. Antiproliferative activity of 1–3 and the parent compound 9 evaluated
by in vitro analysis of percentage of viable K-562 cells with respect untreated
cells (100%) after 72 h of incubation. Respective cytostatic IC50 values (±SD) are
shown in the table. CTR¼DMSO vehicle (<0.1%).
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correlations (negative NOE enhancements), as highlighted in
Figure 5.
In the presence of the ligand–protein interaction, if the ligand
off-rate is fast compared to the bound NOE cross relaxation rate,
the Tr-NOESY signal intensities are the weighted average between
the bound and free cross-peaks intensities14. As shown in Figures
6 and 7, the intensities of NOE cross-peaks of 1 and 2 changes
from negative to zero, upon 14-3-3r addition. This behaviour is
consistent with the interaction between the two molecules and
14-3-3r. The zero intensities of NOEs might be explained by con-
sidering the occurrence of positive NOE peaks due to the pres-
ence of small fractions of either 1 or 2 bound to 14-3-3r.
The analysis of 1 D 1H spectra of either 1 or 2 does not reveal
any significant variations after protein addition. In fact, the con-
centration of the protein-ligand adduct is too small to induce any
perturbation in NMR signals. In addition, it is consistent with the
results obtained by NOESY experiments that support the forma-
tion of complexes with fast ligand off-rates and KD values
> 1 lM15,16.
Compound 1 enhances the nuclear translocation of c-Abl
We have previously shown that the BV02 inhibitor of 14-3-3/c-Abl
interaction is able to promote c-Abl translocation into the nucleus
and to provide antiproliferative effects also in CML cells expressing
the Imatinib-resistant T315I Bcr-Abl construct8. We, therefore, next
assessed nuclear translocation of c-Abl upon treatment with the
most effective 14-3-3 PPI inhibitor 1, using HeLa adenocarcinoma
cells stably overexpressing EGFP-tagged c-Abl (HeLa EGFP-Abl) as a
reporter system11. Confocal microscopy images of HeLa EGFP-Abl
cells clearly show an increase in nuclear EGFP-Abl in the presence
of 1, compared to control (Figure 8(A)). Indeed, the effect of 1 on
EGFP-Abl subcellular localisation, quantitatively scored by analysing
the confocal microscopy images with the Volocity software
(PerkinElmer Life Science, Waltham, MA) (Figure 8(B)), confirmed the
ability of 1 to promote nuclear relocalisation of c-Abl in a dose-
dependent manner. Hence, our molecule was able to promote
strong c-Abl nuclear translocation, even in an experimental setting
in which this protein is overexpressed, suggesting that similar doses
Figure 5. Selected region of 1H-1H NOESY spectra of compound 2 0.5mM (left) and 14-3-3r 0.2mM (right), at pH 7.0 and 298 K. Negative and positive peaks are
shown as red and black contours.
Figure 6. Selected regions of 1H-1H NOESY spectra of compound 1 alone 0.5mM
pH 7.0 (A), and compound 1 0.5mM þ 0.2 eqs. of 14-3-3s pH 7.0 (B).
Figure 7. Selected regions of 1H-1H NOESY spectra of compound 2 alone 0.5mM
pH 7.0 (A), and compound 2 0.5mM þ 0.2 eqs. of 14-3-3s pH 7.0 (B).
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of compound 1 might be largely effective on the c-Abl endogenous
protein, ultimately explaining the antiproliferative effects observed
in Bcr-Abl-expressing CML cells.
Conclusion
Modulation of 14-3-3 proteins is a valuable tool to probe the
regulatory functions of eukaryotic cells, and to develop effective
therapeutic strategies against a number of human diseases. By
exploiting the 4-aminoantipyrine scaffold of 14-3-3r PPI inhibitors
previously developed by our research group, here we designed
and synthesised a number of derivatives endowed with enhanced
chemical stability at physiological conditions. Particularly, com-
pounds 1–3 showed antiproliferative effects against K-562 erythro-
leukemia cell line at low micromolar concentrations. Molecular
modeling suggested a possible binding mode of these com-
pounds that clearly emphasises the role of the carboxylic function.
NMR spectroscopy further confirmed the direct binding of 1 and
2 to recombinant 14-3-3r, while the most promising hit 1 was
found to enhance the nuclear translocation of c-Abl in a dose-
dependent manner by confocal microscopy and intensitomet-
ric analysis.
Overall, this study further confirms the relevance of the 4-ami-
noantipyrine scaffold in the inhibition of 14-3-3r PPI, and high-
lights compound 1 as a valuable hit that is chemically stable at
physiological conditions, and is suitable for further development.
Materials and methods
Chemistry
All commercially available chemicals and solvents were used as
purchased. THF was dried over sodium and benzophenone prior
to use. Anhydrous reactions were run under positive pressure of
dry nitrogen. TLC was carried out using Merck TLC plates silica gel
60 F254 (Merck, Kenilworth, NJ). 1H NMR and 13C NMR were
recorded at 400 and 100MHz, respectively, on a Bruker AC200F
spectrometer (Bruker, Billerica, MA). Proton shift for 1H NMR are
reported in parts per million (d scale) and internally referenced to
the CDCl3 or DMSO signal, at 7.26 and 2.50 ppm, respectively.
Chemical shifts for carbon are reported in parts per million (d
scale) and referenced to the carbon resonances of the solvent
(CDCl3 at d 77.16 and DMSO at d 39.52 ppm). Data are shown as
following: chemical shift, multiplicity (s¼ singlet, d¼doublet,
t¼ triplet, m¼multiplet, and/or multiplet resonances), coupling
constant (J) in Hertz (Hz), and integration. Mass spectra (MS) data
were obtained using an Agilent 1100 LC/MSD VL system (G1946C)
(Agilent Technologies, Palo Alto, CA) by direct injection with a
0.4ml min1 flow rate using a binary solvent system of
MeOH:H2O (95:5). UV detection was monitored at 254 nm.
MS were acquired in positive scanning mode over the mass range
m/z 50–1500.
Synthesis of the reference compound 9
1,2,4-benzenetricarboxylic anhydride (1.06 g, 5.2mmol, and 1
eq) and DMAP (190.58mg, 1.56mmol and 0.3 eq) were added to
a solution of 4-aminoantipyrine (1 g, 5.2mmol, and 1 eq) in DMF
dry (15ml), giving a yellow colour. The mixture was stirred at r.t.
for 72 h. After this time, H2O (20ml) was added and the solution
was stirred 20min until a white precipitate appeared. The white
solid was filtered and washed with H2O and hexane.
Yield: quantitative
1H NMR (400MHz, DMSO, 298 K) (ppm): 13.83 (s, OH); 8.43
(d, J= 7.8 Hz, 1H); 8.32 (s, 1H); 8.10 (d, J= 7.8 Hz, 1H); 7.55 (t,
J= 7.8 Hz, 2H); 7.40 (m, 3H); 3.32 (s, 3H); 2.26 (s, 3H).MS (ESI) m/z:
377.8 [MþH]
Figure 8. The 14-3-3 PPI inhibitor promotes nuclear translocation of c-Abl. (A) Confocal microscopy images showing subcellular localisation of c-Abl in HeLa EGFP-Abl
cells untreated or treated with 1 at 10lM for 24 h. (B) Intensitometric analysis of confocal microscopy images of nuclear EGFP fluorescence on HeLa EGFP-Abl cells
treated with increasing concentrations of 1 for 24 h; bars represent the mean± SEM of the nuclear EGFP fluorescence intensity of seven representative
fields;

p< .0001.
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Synthesis compound 1
Compound 9 (120mg, 0.318mmol, and 1 eq) was dissolved in
a mixture of concentrated HCl (5ml) and glacial acetic acid (5ml).
Sn (226.5mg, 1.908mmol, and 6 eq) was added to the solution,
and the mixture was stirred at 80 C for 24 h before being cooled
to r.t. and filtered through celite. The solution was extracted with
AcOEt (30ml  3). The combined organic phases were washed
with H2O and brine, and dried over anhydrous Na2SO4. The solv-
ent was removed under vacuum to afford 92mg of a white solid.
Yield: 79%
1H NMR (400MHz, DMSO, 298 K) (ppm): 8.22 (m, 2H); 7.78
(m, 1H); 7.51 (m, 2H); 7.38 (m, 3H); 4.87 (s, 2H); 3.17 (s, 3H); 2.23 (s,
3H). 13C NMR (100MHz, DMSO, 298 K) (ppm): 167.13, 166.48,
161.55, 153.09, 147.40, 135.07, 133.13, 132.36, 131.39, 129.67,
127.25, 124.64, 124.36, 107.04, 51.09, 36.03, 11.67. MS (ESI) m/z:
363.8 [MþH], 385.8 [MþNa]
Synthesis compound 2
Oxalyl chloride (0.33ml, 3.738mmol, and 14 eq) was slowly
added to a solution of compound 1 (100mg, 0.267mmol, and
1 eq) in THF (4ml) at 0 C. The mixture was then stirred for
15min, and anhydrous DMF (0.1ml) was added dropwise. The
solution was stirred for 1 h at r.t. and then cooled again to 0 C.
MeOH was added to the reaction and left under stirring for
15min. The reaction was quenched by the addition of NaOH 2 N,
and then extracted with AcOEt (15ml  3). The organic layer was
washed with NaHCO3, brine, dried over Na2SO4 and evaporated
under reduced pressure to obtain 49mg of a brown oil. The mix-
ture was purified by column chromatography (DCM/MeOH 95:5)
to give a yellow solid.
Yield: 47%
1H NMR (400MHz, DMSO, 298K) (ppm): 8.23 (m, 1H); 7.80
(m, 1H); 7.51 (m, 2H); 7.37 (m, 3H); 4.87 (s, 2H); 3.89 (s, 3H); 3.16 (s,
3H); 2.22 (s, 3H).13C NMR (100MHz, DMSO 298 K) (ppm): 166.72,
166.30, 161.44, 151.07, 146.88, 134.47, 132.92, 132.37, 130.41,
129.39, 129.26, 127.16, 125.47, 124.50, 123.18, 108.11, 52.34, 50.31,
35.86, 12.08. MS (ESI) m/z: 377.9 [MþH], 399.8 [MþNa]
Synthesis compound 3
Borane dimethyl sulphide 1 M (0.165ml, 0.165mmol, and 0.6
eq) was added dropwise to a solution at 0 C of compound 1
(100mg, 0.275mmol, and 1 eq) in dry DMSO. The mixture was
stirred overnight at r.t. and then quenched with K2CO3. The solu-
tion was extracted with DCM (15ml  3). The combined organic
layer wasw washed with HCl 1 N, brine, dried over Na2SO4 and
concentrated.
Yield: quantitative
1H NMR (400MHz, DMSO, 298 K) (ppm): 7.74 (s, 1H); 7.59 (m,
2H); 7.52 (m, 2H); 7.38 (m, 3H); 5.42 (s, OH); 4.77 (s, 2H); 4.63(s,
2H); 3.16 (s, 3H); 2.22 (s, 3H).13C NMR (100MHz, DMSO, 298 K)
(ppm): 167.42, 161.73, 153.18, 143.38, 141.43, 135.14, 131.83,
130.67, 129.65, 127.16, 124.53, 123.71, 121.35, 107.53, 62.98, 50.72,
36.09, 11.67. MS (ESI) m/z: 371.9 [MþNa]
Chemical stability of 1
1H NMR spectra were recorded after dilution of 10mg of com-
pound 1 in a mixture of DMSO/D2O 70:30. The chemical shift vari-
ation of the aromatic protons was used to monitor the behaviour
of 1 in solution. NMR spectra were recorded after 2 h and 24 h.
The chemical identity of compound 1 was confirmed by mass
spectrometry after 24 h in solution (MS (ESI) m/z: 363.8 [MþH],
385.8 [MþNa]).
Cell viability assay
As in a previous exercise, in vitro experiments on 14-3-3 PPI inhibi-
tors were carried out using human erythroleukemia cell line K-
56217. Cancer cells were cultured in RPMI medium with 10% FCS.
In order to determine antiproliferative effect of compounds, K-562
cells were seeded at density of 5 104 cells/ml, and treated with
increasing concentrations of selected compounds. Control cells
were treated with the vehicle of the experimental point contain-
ing the highest percentage of DMSO. Cell cultures were main-
tained at 37 C in 5% v/v CO2 for 72 h. Cell number and vitality
were evaluated on cell suspension using the automatic cell coun-
ter NucleoCounterVR (Chemometec, Lillerd, Denmark). Each
experiment was performed at least three times and results were
expressed as mean and standard deviation (±SD).
NMR spectroscopy
NMR spectra were performed at 14.1 T with a Bruker Avance 600
Spectrometer (Bruker) operating at controlled temperature (±
0.2 K) and using a 5mm SEI probe. Chemical shifts were refer-
enced to external 3-(Trimethylsilyl)propionic-2,2,3,3-d4 acid sodium
salt (TMSP-d4). NOESY spectra were obtained by using standard
pulse sequences. NOESY spectra were acquired with a mixing time
of 320ms.
Molecular modelling
The crystallographic structure of 14-3-3r in complex with a phos-
phopeptide coded by PDB ID: 1YWT was used as rigid receptor in
molecular docking simulations, upon removal of the coordinates
of the phosphopeptide and crystallographic water molecules18.
Docking was carried out by the GOLD docking program version
5.0.1 (The Cambridge Crystallographic Data Centre, Cambridge,
UK)19,20 using settings described previously10,11.
Cells, cell culture, and transfections
HeLa cells stably expressing EGFP-Abl (HeLa EGFP-Abl) were
obtained by transfection of HeLa cells with the pCEFL EGFP ABL
wild-type expression vector21, using lipofectamine LTX (Life
Technologies, Carlsbad, CA), according to the manufacturer’s
instructions, followed by selection with 2mg ml 1 G418 (Sigma-
Aldrich, St. Louis, MO) for 3 weeks. HeLa EGFP-Abl were main-
tained in DMEM supplemented with 10% FBS, 2mM L-glutamine,
10,000 Uml1 penicillin, and 10mg ml1 streptomycin and were
constantly kept under selective pressure with 2 mgml1 G418.
Selective medium was replaced with regular growth medium on
the day before experiments.
662 L. IRALDE-LORENTE ET AL.
Immunofluorescence, confocal microscopy, and intensitometric
analysis of fluorescence
Cells were washed with PBS, then fixed with 4% paraformalde-
hyde in PBS for 20min and permeabilised with 0.1% Triton X-100
in PBS for 30min. Nuclei were stained with a solution of 6 lm of
40,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich) in PBS for
10min. Coverslips were mounted in fluorescence mounting
medium (Dako, Agilent Technologies). Samples were visualised on
a TSC SP5 confocal microscope (Leica, 5100000750), installed on
an inverted LEICA DMI 6000CS (10741320) microscope and
equipped with an oil immersion PlanApo 40 1.25NA objective.
Images were acquired using LAS AF acquisition software (Leica
Camera, Wetzlar, Germany). Intensitometric analysis of fluores-
cence was performed using the Quantitation Module of the
Volocity software (PerkinElmer Life Science). Briefly, total nuclear
EGFP fluorescence, defined as EGFP signal co-staining with DAPI
nuclear dye, was measured in seven representative confocal fields
for each experimental condition. The resulting mean values±SEM
are expressed as a percentage of nuclear EGFP fluorescence. Seven
representative fields were acquired and analysed for each sample.
Significance (p values) was assessed by t-test. Asterisks were attrib-
uted for the following significance values:

p< .0001.
Protein expression and purification
The gene encoding for human 14-3-3r (h14–3-3r) cloned in the
pPROEX-HTb vector (including a TEV-cleavable His6-tag) between
the BamHI and NotI restriction site, was a kind gift from Prof. C.
Ottmann (Research group of Chemical Biology, Department of
Biomedical Engineering, Eindhoven University of Technology,
Netherlands). The expression plasmid was introduced by thermal
shock in the Escherichia coli strain BL21(DE3). Transformants were
selected on LB-agar plates added by 100 mgl1 ampicillin.
Bacterial cells were cultured in LB medium, supplemented with
100 mgl1 ampicillin at 37 C under vigorous aeration. When
OD600nm reached values ranging from 0.6 to 0.8, protein over-
expression was induced by adding 0.5mM IPTG to the culture
that was then incubated at 25 C for 16 h (under vigorous aer-
ation). Cells, harvested by centrifugation, were resuspended in
buffer A (250mM NaCl and 50mM Tris-HCl, pH 8) added by
20mM imidazole and lysozyme (0.5mg ml1) and disrupted by
sonication after 1 h of incubation on ice. The soluble cellular frac-
tion, clarified by centrifugation (13500  g, 1 h, 4 C), was purified
by taking advantage of the N-terminal His6-tag using nickel affin-
ity chromatography (HisTrap FF 5ml column, GE Healthcare,
Chicago, IL). The purification protocol relied on a three-step gradi-
ent imidazole concentration (in the same buffer) that showed elu-
tion of the His6-tag h14-3-3r at imidazole concentrations ranging
from 75 to 250mM. Fractions containing the target protein (iden-
tified by SDS-PAGE) were pooled and dialysed in 3mM Tris-HCl,
pH 8 at 4 C. The final protein yield resulted of 87mg l1 bacter-
ial culture.
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